TY - JOUR
T1 - Impact of worsening of aortic insufficiency during HeartMate 3 LVAD support
AU - Imamura, Teruhiko
AU - Narang, Nikhil
AU - Kim, Gene
AU - Nitta, Daisuke
AU - Fujino, Takeo
AU - Nguyen, Ann
AU - Grinstein, Jonathan
AU - Rodgers, Daniel
AU - Ota, Takeyoshi
AU - Raikhelkar, Jayant
AU - Jeevanandam, Valluvan
AU - Sayer, Gabriel
AU - Uriel, Nir
N1 - Funding Information:
TI receives grant support from JSPS KAKENHI: JP20K17143. NU receives grant support from Abbott and Medtronic; GS is a consultant for Medtronic; VJ is a consultant for Abbott.
Publisher Copyright:
© 2020 International Center for Artificial Organs and Transplantation and Wiley Periodicals LLC.
PY - 2021/3
Y1 - 2021/3
N2 - Aortic insufficiency remains a difficult to treat and highly morbid condition even in the era of HeartMate 3 left ventricular assist devices (LVADs). The prognostic nature of the longitudinal progression of aortic insufficiency, however, remains unknown. We prospectively collected data on patients who received HeartMate 3 LVAD implantation, who had assessments of aortic insufficiency using a novel Doppler echocardiography obtained at outflow graft at three (baseline) and 6 months postimplant. Patients with moderate or greater aortic insufficiency at baseline were excluded. The risk of aortic insufficiency progression on 1-year death and readmission for heart failure was investigated. In total, 41 patients (median 51 years old and 29 males) were included. All patients had less than moderate aortic insufficiency at baseline. Of them, 22 patients had worsening aortic insufficiency for 3 months following baseline assessments, which was associated with a significantly higher risk of 1-year death or heart failure readmission rate (41% vs. 11%, P =.023) with a hazard ratio of 3.24 (95% confidence interval 1.02-18.5, P =.038) adjusted for device speed at baseline and destination therapy indication. In patients with HeartMate 3 LVADs, progressive aortic insufficiency may be associated with a higher risk of 1-year death or readmission for heart failure. Close monitoring of patients with baseline aortic insufficiency should be considered as a measure to risk-stratify those for future adverse events.
AB - Aortic insufficiency remains a difficult to treat and highly morbid condition even in the era of HeartMate 3 left ventricular assist devices (LVADs). The prognostic nature of the longitudinal progression of aortic insufficiency, however, remains unknown. We prospectively collected data on patients who received HeartMate 3 LVAD implantation, who had assessments of aortic insufficiency using a novel Doppler echocardiography obtained at outflow graft at three (baseline) and 6 months postimplant. Patients with moderate or greater aortic insufficiency at baseline were excluded. The risk of aortic insufficiency progression on 1-year death and readmission for heart failure was investigated. In total, 41 patients (median 51 years old and 29 males) were included. All patients had less than moderate aortic insufficiency at baseline. Of them, 22 patients had worsening aortic insufficiency for 3 months following baseline assessments, which was associated with a significantly higher risk of 1-year death or heart failure readmission rate (41% vs. 11%, P =.023) with a hazard ratio of 3.24 (95% confidence interval 1.02-18.5, P =.038) adjusted for device speed at baseline and destination therapy indication. In patients with HeartMate 3 LVADs, progressive aortic insufficiency may be associated with a higher risk of 1-year death or readmission for heart failure. Close monitoring of patients with baseline aortic insufficiency should be considered as a measure to risk-stratify those for future adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85093533539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093533539&partnerID=8YFLogxK
U2 - 10.1111/aor.13825
DO - 10.1111/aor.13825
M3 - Article
C2 - 33098153
AN - SCOPUS:85093533539
SN - 0160-564X
VL - 45
SP - 297
EP - 302
JO - Artificial Organs
JF - Artificial Organs
IS - 3
ER -